Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:36 AM
Ignite Modification Date:
2025-12-25 @ 2:36 AM
NCT ID:
NCT00574834
Eligibility Criteria:
Inclusion:
* 48 (24 male / 24 female) with impaired glucose tolerance.
* Impaired blood glucose values as outlined by the American Diabetes Association guideline. Fasting plasma glucose between 100 and 126 mg/dl or 2 hour post prandial glucose between 140 and 200 mg/dl
* BMI \> 25 kgM2
* Age: 20-65 years
* Treated or Untreated hypertension defined as measurement of seated BP at screening visit of systolic BP 120 to 150 and/ or diastolic BP 80 to 100.
Exclusion:
* Patients receiving agents that can increase or lower blood glucose, i.e., metformin, thiazolidinediones, sulfonylureas, glitinides, acarbose, GLP-1 receptor agonists
* Untreated or treated while seated Systolic Blood pressure \>150and/or Diastolic Blood pressure \>100
* Taking hypertensive medications of HCTZ or ACE/ARB
* Allergy to HCTZ, heparin, nitroglycerin or lidocaine
* History of allergy or unacceptable side effects from ACE inhibitors
* Pregnancy or intent to become pregnant during the study
* Smoking
* Subject unable to give voluntary informed consent
Physical Exam Exclusion Criteria
* Clinically significant Cardiac Abnormalities (e.g. Heart Failure, Arrhythmia) from history or ECG in subjects \> 40 years old
* Pneumonia
* Hepatic Failure/Jaundice
* Renal Failure
* Acute Cerebrovascular/ Neurological deficit
* Fever greater than 38.0 C
Screening Laboratory Tests Exclusion Criteria according to protocol
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
20 Years
Maximum Age:
65 Years
Study:
NCT00574834
Study Brief:
Protocol Section:
NCT00574834